FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750762793> ?p ?o ?g. }

• W2750762793 endingPage "1963" @default.
• W2750762793 startingPage "1955" @default.
• W2750762793 abstract "There is scarce evidence comparing novel oral anticoagulants (NOACs) with warfarin in real-world settings in Japan. This study compared the risk of bleeding events among patients with non-valvular atrial fibrillation (NVAF) initiating treatment with NOACs versus warfarin.A retrospective cohort study was conducted using a de-identified electronic health record based database of health claims and Diagnosis Procedure Combination data from 275 consenting hospitals in Japan. NVAF patients newly initiated on oral anticoagulants were eligible. Based on the first prescription, patients were assigned to 5/2.5 mg BID apixaban, 150/110 mg BID dabigatran, 15/10 mg QD rivaroxaban (approved dose lower in Japan compared to Western countries [20/15 mg QD]) or warfarin groups. One-to-one propensity score matching (PSM) was used to balance patient characteristics between warfarin and each NOAC. Patients were followed up to 1 year post-first prescription.Among 38,662 eligible patients, a total of 5977, 5090, and 6726 matched pairs were identified for warfarin versus apixaban, warfarin versus dabigatran, and warfarin versus rivaroxaban, respectively after PSM. Compared to warfarin, apixaban (hazard ratio [HR] 0.586; 95% CI 0.421-0.815), dabigatran (HR 0.617; 0.425-0.895) and rivaroxaban (HR 0.693; 0.514-0.933) were associated with a significantly lower risk of major bleeding. The risk of any bleeding was significantly lower for apixaban (HR 0.782; 0.682-0.896), but not for dabigatran (HR 0.988; 0.860-1.135) or rivaroxaban (HR 0.938; 0.832-1.057) when comparing to warfarin.Among Japanese patients with NVAF, treatment with apixaban 5/2.5 mg BID was associated with a significantly lower risk of major bleeding and any bleeding when compared to warfarin. Treatment with dabigatran 150/110 mg BID or rivaroxaban 15/10 mg QD was associated with a significantly lower risk of major bleeding, but not any bleeding, than warfarin. The potential benefit of individual NOACs in real-world practice needs to be assessed further." @default.
• W2750762793 created "2017-09-15" @default.
• W2750762793 creator A5026801476 @default.
• W2750762793 creator A5029287950 @default.
• W2750762793 creator A5030503300 @default.
• W2750762793 creator A5041777515 @default.
• W2750762793 creator A5072330134 @default.
• W2750762793 creator A5091425023 @default.
• W2750762793 date "2017-09-12" @default.
• W2750762793 modified "2023-09-24" @default.
• W2750762793 title "Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data" @default.
• W2750762793 cites W1539618085 @default.
• W2750762793 cites W1549733185 @default.
• W2750762793 cites W1967121574 @default.
• W2750762793 cites W2012658469 @default.
• W2750762793 cites W2036193982 @default.
• W2750762793 cites W2050306424 @default.
• W2750762793 cites W2069426721 @default.
• W2750762793 cites W2074206824 @default.
• W2750762793 cites W2097854437 @default.
• W2750762793 cites W2121498982 @default.
• W2750762793 cites W2136489990 @default.
• W2750762793 cites W2162508946 @default.
• W2750762793 cites W2359956714 @default.
• W2750762793 cites W2433454023 @default.
• W2750762793 cites W2501651593 @default.
• W2750762793 cites W2509795914 @default.
• W2750762793 cites W2520573665 @default.
• W2750762793 cites W2527161344 @default.
• W2750762793 cites W2572143113 @default.
• W2750762793 cites W4205645630 @default.
• W2750762793 cites W4292280632 @default.
• W2750762793 doi "https://doi.org/10.1080/03007995.2017.1374935" @default.
• W2750762793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28857611" @default.
• W2750762793 hasPublicationYear "2017" @default.
• W2750762793 type Work @default.
• W2750762793 sameAs 2750762793 @default.
• W2750762793 citedByCount "39" @default.
• W2750762793 countsByYear W27507627932018 @default.
• W2750762793 countsByYear W27507627932019 @default.
• W2750762793 countsByYear W27507627932020 @default.
• W2750762793 countsByYear W27507627932021 @default.
• W2750762793 countsByYear W27507627932022 @default.
• W2750762793 countsByYear W27507627932023 @default.
• W2750762793 crossrefType "journal-article" @default.
• W2750762793 hasAuthorship W2750762793A5026801476 @default.
• W2750762793 hasAuthorship W2750762793A5029287950 @default.
• W2750762793 hasAuthorship W2750762793A5030503300 @default.
• W2750762793 hasAuthorship W2750762793A5041777515 @default.
• W2750762793 hasAuthorship W2750762793A5072330134 @default.
• W2750762793 hasAuthorship W2750762793A5091425023 @default.
• W2750762793 hasConcept C126322002 @default.
• W2750762793 hasConcept C167135981 @default.
• W2750762793 hasConcept C17923572 @default.
• W2750762793 hasConcept C207103383 @default.
• W2750762793 hasConcept C2776301958 @default.
• W2750762793 hasConcept C2778661090 @default.
• W2750762793 hasConcept C2778810321 @default.
• W2750762793 hasConcept C2779161974 @default.
• W2750762793 hasConcept C2780638905 @default.
• W2750762793 hasConcept C44249647 @default.
• W2750762793 hasConcept C71924100 @default.
• W2750762793 hasConceptScore W2750762793C126322002 @default.
• W2750762793 hasConceptScore W2750762793C167135981 @default.
• W2750762793 hasConceptScore W2750762793C17923572 @default.
• W2750762793 hasConceptScore W2750762793C207103383 @default.
• W2750762793 hasConceptScore W2750762793C2776301958 @default.
• W2750762793 hasConceptScore W2750762793C2778661090 @default.
• W2750762793 hasConceptScore W2750762793C2778810321 @default.
• W2750762793 hasConceptScore W2750762793C2779161974 @default.
• W2750762793 hasConceptScore W2750762793C2780638905 @default.
• W2750762793 hasConceptScore W2750762793C44249647 @default.
• W2750762793 hasConceptScore W2750762793C71924100 @default.
• W2750762793 hasIssue "11" @default.
• W2750762793 hasLocation W27507627931 @default.
• W2750762793 hasLocation W27507627932 @default.
• W2750762793 hasOpenAccess W2750762793 @default.
• W2750762793 hasPrimaryLocation W27507627931 @default.
• W2750762793 hasRelatedWork W1980640915 @default.
• W2750762793 hasRelatedWork W2049310472 @default.
• W2750762793 hasRelatedWork W2321904733 @default.
• W2750762793 hasRelatedWork W2787309434 @default.
• W2750762793 hasRelatedWork W2789710191 @default.
• W2750762793 hasRelatedWork W2795030171 @default.
• W2750762793 hasRelatedWork W3016213733 @default.
• W2750762793 hasRelatedWork W3160023344 @default.
• W2750762793 hasRelatedWork W4213075745 @default.
• W2750762793 hasRelatedWork W1570353559 @default.
• W2750762793 hasVolume "33" @default.
• W2750762793 isParatext "false" @default.
• W2750762793 isRetracted "false" @default.
• W2750762793 magId "2750762793" @default.
• W2750762793 workType "article" @default.